• S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?

  • Aug 2 2022
  • Durée: 25 min
  • Podcast

Page de couverture de S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?

S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?

  • Résumé

  • Drs John Kane and Christoph U. Correll discuss the major metabolic and neurologic risks associated with antipsychotic medications for patients diagnosed with schizophrenia.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969525). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Schizophrenia https://www.medscape.com/resource/schizophrenia

    Understanding the Effects of Antipsychotics on Appetite Control https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762106/

    Food and Drug Administration's Obesity Drug Guidance Document https://www.ahajournals.org/doi/10.1161/circulationaha.111.028381

    Risk of Weight Gain for Specific Antipsychotic Drugs: A Meta-analysis https://www.nature.com/articles/s41537-018-0053-9

    Diabetes and Schizophrenia https://link.springer.com/article/10.1007/s11892-015-0704-4

    Brain Insulin Action: Implications for the Treatment of Schizophrenia https://www.sciencedirect.com/science/article/abs/pii/S0028390819301960?via%3Dihub

    Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis -- A Longitudinal Study https://academic.oup.com/schizophreniabulletin/article-abstract/47/6/1772/6291438

    Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission https://pubmed.ncbi.nlm.nih.gov/25004198/#:~:text=Conclusions%3A%20Body%20mass%20index%20was,be%20explored%20in%20prospective%20studies

    Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort https://pubmed.ncbi.nlm.nih.gov/30257079/

    Incidence and Severity of Tardive Dyskinesia Increase With Age https://jamanetwork.com/journals/jamapsychiatry/article-abstract/492775

    Extrapyramidal Symptoms With Atypical Antipsychotics: Incidence, Prevention and Management https://reference.medscape.com/medline/abstract/15733025

    Voir plus Voir moins
activate_primeday_promo_in_buybox_DT

Ce que les auditeurs disent de S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.